NATR NATURES SUNSHINE PRODUCTS INC
Pharmaceutical Preparations · Nasdaq · SEC CIK 275053 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY1.2%
TTM net income YoY-2.9%
TTM EPS YoY1.2%
Revenue 3-yr CAGR3.0%
Net income 3-yr CAGR22.0%
Margins
Gross margin73.1%
Operating margin5.3%
Net margin3.1%
FCF margin2.2%
EBITDA margin8.1%
Returns
ROE8.8%
ROA5.5%
ROIC (approx.)21.5%
Asset turnover1.80x
Leverage & solvency
Liabilities / assets36.0%
Debt / equity0.00x
Current ratio2.56x
Interest coverage176.76x
Cash quality & payout
Operating cash flow / net income1.34x
Accruals ratio-1.9%
Payout ratio—
Capex / revenue1.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $480.14M | $454.36M |
| Cost of revenue | $132.42M | $129.68M |
| Gross profit | $347.72M | $324.69M |
| R&D expense | $1.90M | $1.70M |
| SG&A expense | $178.39M | $164.00M |
| Operating income | $24.74M | $20.09M |
| Interest expense | $98,000 | $146,000 |
| Pretax income | $29.81M | $18.43M |
| Income tax | $9.36M | $10.53M |
| Net income | $19.52M | $7.70M |
| EBITDA | $38.59M | $34.31M |
| EPS (basic) | 1.08 | 0.41 |
| EPS (diluted) | 1.06 | 0.40 |
| Weighted avg. shares (diluted) | 18.47M | 19.09M |
| Balance sheet | ||
| Cash & equivalents | $93.89M | $84.70M |
| Receivables | $8.60M | $9.48M |
| Inventory | $68.31M | $59.44M |
| Current assets | $178.84M | $160.58M |
| PP&E, net | $32.91M | $39.59M |
| Total assets | $261.15M | $240.85M |
| Current liabilities | $78.54M | $65.69M |
| Total liabilities | $99.59M | $79.86M |
| Shareholders' equity | $161.55M | $155.31M |
| Shares outstanding | 17.51M | 18.48M |
| Cash flow statement | ||
| Operating cash flow | $35.32M | $25.30M |
| Capital expenditure | $6.48M | $10.97M |
| Free cash flow | $28.84M | $14.33M |
| Investing cash flow | -$6.48M | -$10.97M |
| Financing cash flow | -$23.77M | -$9.90M |
| Depreciation & amortization | $13.84M | $14.22M |
| Stock-based compensation | $5.78M | $4.79M |
| Share buybacks | $16.31M | $8.86M |
Free plan shows the latest 2 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.